Widely used:Recently Viewed
Clear All$0.06
$0.00
(2.05%)
As on 24-Apr-2025 12:19EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$86 Mln
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-61.90 Mln
EBITDA
$-35.33 Mln
Net Profit
$-76.75 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW)
| -60.58 | 29.86 | -66.34 | -88.43 | -28.46 | -4.13 | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW)
| -88.30 | 44.44 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and... cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention"deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. Address: 10080 N. Wolfe Road, Cupertino, CA, United States, 95014 Read more
Founder, CEO, President & Director
Dr. Laxminarayan Bhat Ph.D.
Founder, CEO, President & Director
Dr. Laxminarayan Bhat Ph.D.
Headquarters
Cupertino, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW) is $0.06 (NASDAQ) as of 24-Apr-2025 12:19 EDT. Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW) has given a return of -28.46% in the last 3 years.
Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW) has a market capitalisation of $ 86 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW) and enter the required number of quantities and click on buy to purchase the shares of Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW).
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention"deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California. Address: 10080 N. Wolfe Road, Cupertino, CA, United States, 95014
The CEO & director of Dr. Laxminarayan Bhat Ph.D.. is Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW), and CFO & Sr. VP is Dr. Laxminarayan Bhat Ph.D..
There is no promoter pledging in Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Reviva Pharmaceuticals Holdings Inc Warrants (RVPHW) was $0 Mln.
